KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) The Cambridge based company, on Monday summarized first quarter financial results before market open.
The company communicated loss for the first quarter of $ 7.34 million or $ 0.42 per share, compared to loss of $ 5.03 million or $ 0.47 per share for the year-ago quarter.
KALV posted revenue for first quarter fell 9.41 percent to $ 3.37 million from $ 3.72 million in the same quarter last year
Wall street analysts are predicting, KALV to report 1Q20 loss of $ 0.62 per share from revenue of $ 3.22 million.
Analysts estimates are from Thomson Reuters, exclude one time gain or loss.
Andrew Crockett, Chief Executive Officer of KalVista, Our second ongoing Phase 2 trial, with KVD900 for on-demand treatment of hereditary angioedema attacks is currently enrolling, and we continue to expect to complete that trial late this year.